Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Abdel-Daim et al
Phase 2 documented a clear dose-response: 9.1% at 2.4 mg versus 10.8% at 4.5 mg at 26 weeks (Lau et al., 2021)
This indicates that CTHRC1 not only recruits macrophages but also reprograms them into an immunosuppressive M2 state, which supports cancer metastasis, making CTHRC1 a potential therapeutic target for disrupting this pro-tumorigenic interaction in ovarian cancer (59)
It has not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease, and we treat its use as investigational and as part of an individualized wellness plan
Free UK shipping over 25. A corrective treatment to fade dark spots & even skin tone
US$ 26.69
US$ 25.89
US$ 26.46
US$ 26.96
